^
    2d
    MAIA: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma (clinicaltrials.gov)
    P3, N=737, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2d
    A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (Dara@Home) (ACTRN12624001468516)
    P2, N=50, Not yet recruiting, Australasian Myeloma Research Consortium
    New P2 trial
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2d
    FIL_DALYA: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (clinicaltrials.gov)
    P2, N=28, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    CD38 positive
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3d
    To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma (clinicaltrials.gov)
    P3, N=284, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    lenalidomide • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    10d
    Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL (clinicaltrials.gov)
    P2, N=20, Recruiting, Eastern Cooperative Oncology Group | Trial completion date: Oct 2024 --> Jun 2027 | Trial primary completion date: Oct 2024 --> Jun 2027
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    cytarabine • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    10d
    PRISM: DARA RVD For High Risk SMM (clinicaltrials.gov)
    P2, N=61, Active, not recruiting, Omar Nadeem, MD | Recruiting --> Active, not recruiting | Trial completion date: Mar 2029 --> Dec 2030 | Trial primary completion date: Mar 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Chr t(4;14) • Chr t(14;16)
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    15d
    Trial in Progress: Iberdomide and Daratumumab As Maintenance Therapy after an Autologous Stem Cell Transplant for Multiple Myeloma (the IBEX Trial) (ASH 2024)
    Background and Significance : Lenalidomide (LEN) maintenance after autologous stem cell transplant (ASCT) therapy extends disease control in multiple myeloma (McCarthy PL, et al...EHA 2024 abstr 958).The IBEX trial, described herein, is a Phase II trial designed to evaluate the combination of IBER and subcutaneous DARA (IBER+DARA(SC)) as maintenance therapy in myeloma pts who remain MRD(+) following ASCT.Study Design and Methods : The primary objective is to assess the efficacy of post-ASCT IBER+DARA(SC) maintenance as reflected by capacity to induce MRD(-) responses using the commercially available ClonoSEQ assay with a 10-5 sensitivity...Subcutaneous DARA is weekly for cycles 1-2, every other week for cycles 3-6, then monthly thereafter, following the DARA schedule currently being used in the S1803 trial. Patients will be treated for up to 2 years on this study (26 cycles of therapy).This study is registered with ClinicalTrials.gov : ID NCT06107738
    Clinical
    |
    CRBN (Cereblon)
    |
    clonoSEQ
    |
    lenalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    17d
    CEPHEUS: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy (clinicaltrials.gov)
    P3, N=395, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2027 --> Jan 2026
    Trial completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    18d
    SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Roswell Park Cancer Institute | Initiation date: Nov 2024 --> Feb 2025
    Trial initiation date • Combination therapy
    |
    carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • SX-682
    20d
    A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=316, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Jun 2027 --> Apr 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • forimtamig (RG6234)
    25d
    Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Alabama at Birmingham | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    Daratumumab Maintenance Therapy for Improving Survival in Patients with Light Chain Amyloidosis, EMILIA Trial (clinicaltrials.gov)
    P2, N=96, Recruiting, Mayo Clinic | Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    Minimal Residual Disease Testing in Relapsed Systemic AL Amyloidosis (ASH 2024)
    Background The only FDA-approved therapy for systemic light chain (AL) amyloidosis is daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (i.e., Dara-CyBorD)...At the time of the MRD test, 30 (58.8%) patients were on active surveillance, 10 (19.6%) were on daratumumab and 9 (17.6%) on venetoclax...In patients with relapsed AL, MRD negativity is correlated with a better hematological response and could potentially play a role in clinical trial design. The impact of gender on MRD status remains an important area for further study.
    Minimal residual disease
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • bortezomib • cyclophosphamide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=290, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Sep 2024 --> Aug 2025
    Trial primary completion date
    |
    pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=252, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • GEN3014
    2ms
    Rapid DFLC Response Predict CHR in AL Amyloidosis (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Peking University People's Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    bortezomib • cyclophosphamide • Darzalex (daratumumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    AQUILA: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P3, N=390, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2025 --> Dec 2025
    Trial completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=9, Completed, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Oct 2024 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538
    2ms
    DARATALL-VHR: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (clinicaltrials.gov)
    P2, N=31, Recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Not yet recruiting --> Recruiting | Trial completion date: Jan 2029 --> Oct 2029 | Initiation date: May 2024 --> Oct 2024 | Trial primary completion date: Jan 2029 --> Oct 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov)
    P2, N=130, Recruiting, University of Heidelberg Medical Center | N=70 --> 130 | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2026 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance (SWOG-Fall 2024)
    R A N D O M I Z A T I O N Arm 1: Lenalidomide VRd-Lite (Bortezomib + Lenalidomide + Dexamethasone) Arm 2: Arm 3: DRd (Daratumumab and hyaluronidase-fihj + Lenalidomide + Dexamethasone) DRd (Daratumumab and hyaluronidase-fihj + Lenalidomide + Dexamethasone) Lenalidomide Daratumumab and hyaluronidase-fihj + Lenalidomide FALL 2024 SWOG MYELOMA 23 S2209/III Secondary Endpoints: To compare PFS in Arm 1 versus Arm 3. Among the nine patients on the DRD-DR arm evaluated for adverse events, there has been one treatment-related death from heart failure. Two additional patients experienced a Grade 4 adverse event as maximum grade (both hematologic).
    Clinical • P3 data
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS study (DGHO 2024)
    Introduction: In the phase 3 PERSEUS study, subcutaneous (SC) DARA + VRd (D-VRd) induction/consolidation (ind/consol) and D-R maintenance (maint) increased PFS and depth of response (≥ complete response [CR] and MRD negativity [neg]) vs VRd ind/consol and R maint for TE NDMM. Higher rates of deep (10 –6 ) and sustained MRD neg with D-VRd ind/consol and D-R maint vs VRd ind/consol and R maint translated to improved PFS. These data support D-VRd and D-R maint as a new standard of care in TE NDMM and highlight the benefit of DARA SC in maint.
    Clinical • Minimal residual disease
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    Daratumumab (DARA)/bortezomib/lenalidomide/dexamethasone (D-VRd) with D-R maintenance therapy (Maint) in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of the PERSEUS study based on cytogenetic risk (DGHO 2024)
    Introduction: In the phase 3 PERSEUS study, subcutaneous (SC) DARA + VRd induction/consolidation (ind/consol) and D-R maint improved progression-free survival (PFS) and rates of deep, durable responses, including minimal residual disease (MRD) negativity (neg) vs VRd ind/consol and R maint in TE NDMM, regardless of cytogenetic risk. Adding DARA SC to VRd ind/consol and R maint significantly improved PFS and sustained response rates, supporting D-VRd ind/consol and D-R maint as a new SOC for TE NDMM, regardless of cytogenetic risk status.
    Clinical
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    CEPHEUS: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy (clinicaltrials.gov)
    P3, N=395, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Aug 2025 --> May 2024
    Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=761, Recruiting, Pfizer | Active, not recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    Daratumumab in HLA Desensitization Prior to Transplantation (clinicaltrials.gov)
    P2, N=6, Enrolling by invitation, Barry A. Boilson | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3ms
    ALCYONE: A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma (clinicaltrials.gov)
    P3, N=706, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    bortezomib • Darzalex (daratumumab) • prednisone • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    3ms
    Rapid dFLC Response Predict CHR in AL Amyloidosis (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Peking University People's Hospital
    New trial
    |
    bortezomib • cyclophosphamide • Darzalex (daratumumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3ms
    SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Roswell Park Cancer Institute
    New P1 trial
    |
    carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • SX-682
    3ms
    MYLENE: Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) (clinicaltrials.gov)
    P=N/A, N=96, Completed, iOMEDICO AG | Active, not recruiting --> Completed | N=250 --> 96
    Trial completion • Enrollment change
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3ms
    ANDROMEDA: A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P3, N=416, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2024 --> Nov 2024
    Trial completion date • Combination therapy
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3ms
    Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies (clinicaltrials.gov)
    P1, N=8, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3ms
    Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients with Renal Failure (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Augusta University | Initiation date: Jan 2024 --> Oct 2024
    Trial initiation date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3ms
    iinnovate-3: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=15, Completed, Takeda | Active, not recruiting --> Completed | N=58 --> 15 | Trial completion date: Mar 2025 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • modakafusp alfa (TAK-573)
    3ms
    MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=761, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    3ms
    DARATUMUMAB (DARA) + BORTEZOMIB/ LENALIDOMIDE/DEXAMETHASONE (VRD) IN TRANSPLANT-ELIGIBLE (TE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): ANALYSIS OF MINIMAL RESIDUAL DISEASE (MRD) IN THE PERSEUS TRIAL (SIE 2024)
    In the primary analysis of the phase 3 PERSEUS study, subcutaneous DARA (DARA SC) + VRd (D-VRd) induction/consolidation (ind/consol) and D-R maintenance improved PFS and increased depth of response (≥CR and MRD neg) compared to VRd ind/consol and R maintenance for TE NDMM. During maintenance, a greater proportion of pts with MRD-pos status achieved MRD neg with D-R vs R. The higher rates of deep (10–6) and sustained MRD neg achieved with D-VRd ind/consol and D-R maintenance vs VRd ind/consol and R maintenance translated to a clinically meaningful benefit of improved PFS. These data further support D-VRd and D-R maintenance as a new SOC for TE pts with NDMM and highlight the benefit of DARA SC in maintenance.
    Clinical • Minimal residual disease
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    4ms
    aMMbition: A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Recruiting, Janssen Research & Development, LLC
    New P2 trial
    |
    lenalidomide • bortezomib • cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    4ms
    Therapy-Related B-Lymphoblastic Leukemia Following Treatment for Multiple Myeloma With Unusual Surface Light Chain Expression (CAP 2024)
    He received lenalidomide/bortezomib/dexamethasone chemotherapy, followed by autologous stem cell transplant and monthly subcutaneous daratumumab/lenalidomide/dexamethasone therapy. Also, the patient received chemotherapy for myeloma. Although it is not a WHO-recognized disease entity, previous publications suggest that it may represent a therapy-related B-ALL following myeloma treatment.
    IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • KDM6A (Lysine Demethylase 6A) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    4ms
    MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs)
    4ms
    Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xpovio (selinexor) • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    5ms
    IFM 2021-01: Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=74, Recruiting, University Hospital, Lille | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    lenalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv)
    5ms
    FT576 in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Fate Therapeutics | Recruiting --> Active, not recruiting | N=168 --> 31
    Enrollment closed • Enrollment change • Combination therapy
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT576